- Home
- BGLC vs BCDA Comparison
BGLC vs BCDA Comparison
Compare BGLC & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- BCDA
- Stock Information
- Founded
- BGLC 2017
- BCDA N/A
- Country
- BGLC Malaysia
- BCDA United States
- Employees
- BGLC N/A
- BCDA N/A
- Industry
- BGLC Medical Specialities
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- BGLC Health Care
- BCDA Health Care
- Exchange
- BGLC Nasdaq
- BCDA Nasdaq
- Market Cap
- BGLC 7.6M
- BCDA 7.9M
- IPO Year
- BGLC N/A
- BCDA N/A
- Fundamental
- Price
- BGLC $0.37
- BCDA $2.68
- Analyst Decision
- BGLC
- BCDA Strong Buy
- Analyst Count
- BGLC 0
- BCDA 1
- Target Price
- BGLC N/A
- BCDA $25.00
- AVG Volume (30 Days)
- BGLC 117.9K
- BCDA 73.1K
- Earning Date
- BGLC 11-20-2024
- BCDA 11-06-2024
- Dividend Yield
- BGLC N/A
- BCDA N/A
- EPS Growth
- BGLC N/A
- BCDA N/A
- EPS
- BGLC N/A
- BCDA N/A
- Revenue
- BGLC $9,183,168.00
- BCDA $428,000.00
- Revenue This Year
- BGLC N/A
- BCDA $6.92
- Revenue Next Year
- BGLC N/A
- BCDA N/A
- P/E Ratio
- BGLC N/A
- BCDA N/A
- Revenue Growth
- BGLC N/A
- BCDA 0.71
- 52 Week Low
- BGLC $0.31
- BCDA $1.96
- 52 Week High
- BGLC $3.39
- BCDA $23.25
- Technical
- Relative Strength Index (RSI)
- BGLC 32.80
- BCDA 49.01
- Support Level
- BGLC $0.38
- BCDA $2.39
- Resistance Level
- BGLC $0.49
- BCDA $2.90
- Average True Range (ATR)
- BGLC 0.02
- BCDA 0.18
- MACD
- BGLC -0.01
- BCDA -0.00
- Stochastic Oscillator
- BGLC 5.94
- BCDA 53.70
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).